Galmed Pharmaceuticals Reports Promising Results from Aramchol Meglumine Study

Galmed Pharmaceuticals ( (GLMD) ) just unveiled an update.

On November 18, 2025, Galmed Pharmaceuticals announced significant top-line results from its AM-001 Phase 1 Bioavailability Study of Aramchol meglumine. The study revealed that Aramchol meglumine granules have a considerably higher bioavailability compared to Aramchol free acid tablets, with potential implications for improved patient adherence and reduced drug costs. These findings support the advancement of Aramchol meglumine into Phase 2 oncology studies planned for the first half of 2026, marking a pivotal step in the drug’s development and commercialization strategy.

Spark’s Take on GLMD Stock

According to Spark, TipRanks’ AI Analyst, GLMD is a Underperform.

Galmed Pharmaceuticals faces significant financial challenges, with no revenue and continuous losses, which heavily impact its stock score. Poor technical indicators and negative valuation metrics further weigh down the score. The strong equity position offers some support but is overshadowed by the lack of operational efficiency and profitability.

To see Spark’s full report on GLMD stock, click here.

More about Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing treatments for liver, cardiometabolic, and gastrointestinal oncology indications. The company is primarily engaged in the development of Aramchol, a drug aimed at treating liver diseases, with plans to expand its application to oncological indications. Galmed is also pursuing opportunities to diversify its product pipeline targeting cardiometabolic conditions.

Average Trading Volume: 1,635,573

Technical Sentiment Signal: Strong Sell

Current Market Cap: $5.7M

See more insights into GLMD stock on TipRanks’ Stock Analysis page.